According to our new research study on "Vaccine Adjuvants Market Size and Forecast to 2030 -Impact and Country Analysis - by Type, Packaging Type, Route of Administration, and End User," the market is expected to grow from US$ 2,482.39 million in 2022 to US$ 6,931.55 million by 2030; it is estimated to record a CAGR 13.7% during 2022-2030. Support for developments in adjuvant studies and collaborative efforts for product launches creates opportunities for the vaccine adjuvant market is a standalone factor responsible for influential market growth driving the vaccine adjuvants market growth. However, product recalls and adverse effects restrict the market's growth.

Market Trend

Technological Advancements

Currently, in the US, aluminum salt or gel-based adjuvants are used predominantly in licensed vaccines. Monophosphoryl lipid A (MPL) adjuvant and hydrophobic copolymers are some examples of these components. Hydrophobic microspheres pose challenges during vaccine production. The problems include a lot of environmental waste disposal and contamination issues, and it is also time-consuming, costly, and inefficient. Therefore, manufacturers are emphasizing developing novel technologies to avoid using organic solvents. For example, Aphios' Vaccine Adjuvant Technology encompasses nanotechnology, and its production includes the use of supercritical, critical, or near-critical fluids with or without polar cosolvents such as ethanol [referred to as superfluids (SFS)]. Biodegradable biopolymers are dissolved in SFS and mixed with subunit vaccines in an aqueous solution or as a slurry of nanoparticles. Therefore, such new vaccine adjuvant technologies are being developed for making biodegradable polymer nanospheres (PNS) through novel processes, which allows vaccine manufacturers to rule out the use of organic solvents. Thus, technological advancements are likely to bring new trends in the vaccine adjuvants market in the coming years.

Approvals of Veterinary Vaccine Adjuvants

Vaccinating animals against common diseases remains the most successful method worldwide to prevent financial and other losses from infectious diseases in animal farming. The number of regulatory approvals for adjuvants for veterinary vaccines is increasing with the growing focus among manufacturers on developing vaccines with greater efficacy and stability. Montanide is one of the known veterinary vaccine adjuvants. The Montanide adjuvant range is based on three core technologies-emulsions, micro-emulsions, and polymers.

Below is a list of approved veterinary vaccine adjuvants in India from January 2020 to September 2022.

Veterinary Vaccines Adjuvants for Veterinary Infections

Company Name Product Disease Indication

Boehringer Ingelheim Inactivated Vaccine in Oil Adjuvant Newcastle Disease, Disease Bronchitis, Infectious Bursal Disease, and Avial Viral Arthritis

Virbac Animal Health Pvt. Ltd. Inactivated Vaccine in Oil Adjuvant Newcastle Disease and Ranikhet Disease

Virbac Animal Health Pvt. Ltd. Inactivated Vaccine in Oil Adjuvant Newcastle Disease, Ranikhet Disease, Avian infectious Bronchitis, and Combined Newcastle Disease

Source: CDSCO

Therefore, an upsurge in adjuvant approvals for veterinary vaccines accelerates the overall market growth of vaccine adjuvants.

Adjuvant Class-Based Insights

By adjuvant class, the vaccine adjuvants market is segmented as mineral salt-based adjuvants, emulsion adjuvants, liposome adjuvants, and others. The mineral salt-based adjuvants segment held a larger market share in 2022 and is anticipated to register the highest CAGR during the forecast period. Mineral salts such as insoluble aluminum salts and calcium phosphates are used as adjuvants in vaccine formulations. Aluminum salt-based adjuvants help induce early and long-lasting protective immunity. Aluminum adjuvants indicated for use in human vaccines are regulated by the US Food and Drug Administration (FDA), and small amounts of aluminum are added to help the body build higher immunogenicity than the antigen alone in the vaccine. Mineral salt adjuvants formulation at inflammatory site produces fast immune response by release of pro-inflammatory cytokines. Therefore, the ability of mineral salt-based adjuvants to induce a fast immune response toward antigens favors the vaccine adjuvants market growth.

SPI Pharma Inc, GSK Plc, CSL Ltd, Seppic SA, Hawaii Biotech Inc, Dynavax Technologies Corp, InvivoGen SAS, Croda International Plc, Novavax Inc., and Phibro Animal Health Corp are among the key companies operating in the vaccine adjuvants market. Leading players adopt strategies such as launching new products, expanding and diversifying their market presence, and expanding new customer base to tap prevailing business opportunities.

Contact Us

Contact Person: Sameer Joshi

Phone: +1-646-491-9876

Email Id: sales@premiummarketinsights.com